Corrigendum to ‘Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study’ [Eur J Canc 81 (2017) 17–25]

Chau, Ian; Peck‐Radosavljevic, Markus; Borg, Christophe; Malfertheiner, Peter; Seitz, Jean François; Park, Joon Oh; Ryoo, Baek Yeol; Yen, Chia Jui; Kudo, Masatoshi; Poon, Ronnie Tung‐Ping; Pastorelli, Davide; Blanc, Jean Frédéric; Chung, Hyun Cheol; Baron, Ari David; Okusaka, Takuji; Bowman, Lee; Cui, Zhanglin Lin; Girvan, Allicia C.; Abada, Paolo; Yang, Lingwei

doi:10.1016/j.ejca.2018.06.002

Cited by 6 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 5-year survival for patients with HCC following surgical resection is only 30% [5]. Targeted drug therapies for HCC are limited and include sorafenib and lenvatinib [6,7]. Therefore, compared with other malignant tumors, the prognosis for patients with HCC remains poor and because the development of targeted therapy for patients with HCC is limited, there is a need to discover new biomarkers and drug targets.…”

Section: Introductionmentioning

confidence: 99%

Increased Expression of Serine Hydroxymethyltransferase 2 (SHMT2) is a Negative Prognostic Marker in Patients with Hepatocellular Carcinoma and is Associated with Proliferation of HepG2 Cells

Tang

Pang

et al. 2019

Med Sci Monit

View full text Add to dashboard Cite

Background Serine hydroxymethyltransferase 2 (SHMT2) is a key enzyme in one-carbon cell metabolism, including in liver cancer. However, the associations between SHMT2 expression at the gene and protein level and prognosis in patients with hepatocellular carcinoma (HCC) remains unknown. This study aimed to investigate the expression levels of SHMT2 in tumor tissue samples from patients with HCC and clinical outcome and the effects of silencing the expression of the SHMT2 gene in HepG2 cells. Material/Methods Expression levels of SHMT2 were evaluated in 144 cases of HCC using immunohistochemistry and correlated with clinicopathological factors using the chi-squared (χ 2 ) test. The prognostic significance of SHMT2 expression was analyzed by univariate analysis and multivariate analysis. Twenty pairs of HCC tissue and adjacent normal liver tissue were compared for SHMT2 expression levels using quantitative reverse transcription polymerase chain reaction (qRT-PCR). HepG2 cells underwent SHMT2 gene silencing and MTT and transwell assays investigated cell proliferation and migration. Western blot was used to detect the expression of markers of epithelial-mesenchymal transition (EMT). Results Expression levels of SHMT2 in HCC tissues were significantly correlated with tumor grade and hepatitis B virus (HBV) infection, and increased expression was an independent negative prognostic factor in patients with HCC (P=0.003). Increased expression of the SHMT2 gene promoted the proliferation and migration of the HepG2 HCC cell line. Conclusions Increased expression of SHMT2 was a negative prognostic biomarker in patients with HCC. Expression of the SHMT2 gene promoted the proliferation and migration of HepG2 HCC cells.

show abstract

Section: Introductionmentioning

confidence: 99%

Increased Expression of Serine Hydroxymethyltransferase 2 (SHMT2) is a Negative Prognostic Marker in Patients with Hepatocellular Carcinoma and is Associated with Proliferation of HepG2 Cells

Tang

Pang

et al. 2019

Med Sci Monit

View full text Add to dashboard Cite

show abstract

“…Two full publications (38,39) of the REACH trial were retained as well as one full publication (40) of the REACH-2 trial (Table 2). REACH is a phase III trial that compared second-line ramucirumab + BSC to placebo + BSC.…”

Section: Ramucirumab/bsc Versus Placebo/bscmentioning

confidence: 99%

“…In contrast, increased AST, hyperbilirubinemia, and increased blood bilirubin occurred more often in the placebo group. Chau et al (39) reported participantfocused outcomes from the REACH trial using the FACT Hepatobiliary Symptom Indexes. There were no significant differences between the two arms of the trial.…”

Section: Ramucirumab/bsc Versus Placebo/bscmentioning

confidence: 99%

Non-surgical management of advanced hepatocellular carcinoma: A systematic review by Cancer Care Ontario

Meyers

Knox

Cosby

et al. 2021

CanLivJ

View full text Add to dashboard Cite

BACKGROUND: Hepatocellular carcinoma (HCC) is a global health problem, accounting for 4.7% of all new cancer cases and 8.2% of all cancer deaths worldwide in 2018. Resection and transplantation are the only modalities that offer a cure for HCC; however, most patients are diagnosed at an advanced stage, precluding these curative treatments. A number of local (ie, ablative therapies) and/or local-regional therapies (ie, chemo-embolization) are used and followed by systemic therapy for advanced or progressive disease. Other treatments are available, but their efficacy compared with these standards is not well known. METHODS: Literature searches (1/2000 to 1/2020 or 1/2005 to 1/2020, depending on the specific systematic review question) were conducted, including MEDLINE, Embase and the Cochrane Database of Systematic Reviews. RESULTS: Over 30,000 articles were identified. In total, 49 studies were included in the systematic review. CONCLUSIONS: There is no evidence to support the addition of sorafenib to any local or regional therapy. First-line systemic therapy options for unresectable or metastatic HCC include sorafenib, lenvatinib, and atezolizumab + bevacizumab. Regorafenib or cabozantinib provide survival benefits when given as second-line treatment.

show abstract

“…The outcome for ramucirumab was disappointing, showing no significant OS benefit [48, 49]; however, a subset analysis suggested potential benefits for patients with an initial high AFP level (> 400 ng/mL). Based on those findings, a follow-up phase III trial (REACH-2, NCT02435433) selectively enrolled patients with AFP > 400 ng/mL.…”

Section: Individualized Medicine and Potential Biomarkers In Hccmentioning

confidence: 99%

Implications of Immunotherapy in Hepatobiliary Tumors

2019

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer-related death worldwide. Upon ineligibility for resection, liver transplantation, or locoregional therapies, sorafenib has been the only systemic treatment option of advanced HCC for more than a decade. Immunotherapy is an evolving HCC treatment option that has shown promise in treatment efficacy at an acceptable safety profile during several preceding phase I/II trials. Numerous clinical trials of immune checkpoint inhibitors (ICPIs) alone, in combination of two, or combined with other targeted or locoregional therapies are ongoing. Encouraging results of two-phase III trials testing pembrolizumab or nivolumab versus standard care therapy even resulted in Food and Drug Administration approval for second-line treatment of advanced HCC. ICPIs may open new avenues to the treatment of hepatobiliary tumors, alone or in combination.

show abstract

Corrigendum to ‘Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study’ [Eur J Canc 81 (2017) 17–25]

Cited by 6 publications

References 0 publications

Increased Expression of Serine Hydroxymethyltransferase 2 (SHMT2) is a Negative Prognostic Marker in Patients with Hepatocellular Carcinoma and is Associated with Proliferation of HepG2 Cells

Increased Expression of Serine Hydroxymethyltransferase 2 (SHMT2) is a Negative Prognostic Marker in Patients with Hepatocellular Carcinoma and is Associated with Proliferation of HepG2 Cells

Non-surgical management of advanced hepatocellular carcinoma: A systematic review by Cancer Care Ontario

Implications of Immunotherapy in Hepatobiliary Tumors

Contact Info

Product

Resources

About